AAAAI 2024: Insights on Advancements in Food Allergy Management AAAAI 2024: Insights on Advancements in Food Allergy Management
Dr David A. Hill shares highlights from AAAAI 2024, including the new indication for omalizumab and fresh data on oral immunotherapy.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 1, 2024 Category: Consumer Health News Tags: Allergy & Clinical Immunology MDAngle Source Type: news
UCLA Samueli to lead $4 million cell research project funded by Chan Zuckerberg Initiative
Key takeawaysThe grant will fund a three-year collaboration among researchers at UCLA, USC and Caltech to advance cell and tissue engineering technologies.The project, led by UCLA ’s Dino Di Carlo, will engineer, manipulate and analyze cell-to-cell interactions that underlie complex multicellular systems in the body.Di Carlo said he aims for the collaboration to develop into a long-term partnership across institutions to advance biotechnology in Los Angeles.The Chan Zuckerberg Initiativetoday announced a $4 million grant to support research led by the UCLA Samueli School of Engineering that will examine cellular behavio...
Source: UCLA Newsroom: Health Sciences - February 29, 2024 Category: Universities & Medical Training Source Type: news
Investigational Immunotherapy Combo Shows Promise for Advanced Solid Tumors
(MedPage Today) -- An investigational combination of CTLA-4 and PD‐1 checkpoint inhibitors demonstrated "encouraging" tumor activity, as well as a manageable safety profile, in patients with advanced/metastatic solid tumors, according to... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 26, 2024 Category: Hematology Source Type: news
New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies
Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, egg, milk and wheat that people as young as 1 year consumed without an allergic reactionThe U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergiesAllergic reactions can be life-threatening and it is estimated that food-related anaphylaxis results in 30,000 medical events treated in emergency rooms in the U.S. each year1-3Basel, 25 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today data from Stage 1 of the N...
Source: Roche Investor Update - February 25, 2024 Category: Pharmaceuticals Source Type: news
New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies
Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, egg, milk and wheat that people as young as 1 year consumed without an allergic reactionThe U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergiesAllergic reactions can be life-threatening and it is estimated that food-related anaphylaxis results in 30,000 medical events treated in emergency rooms in the U.S. each year1-3Basel, 25 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today data from Stage 1 of the N...
Source: Roche Media News - February 25, 2024 Category: Pharmaceuticals Source Type: news
Rice University Researchers Are Developing an Implantable Cancer Therapeutic Device That May Reduce Cancer Deaths by Half
Immunotherapy device could also enable clinical laboratories to receive in vivo biomarker data wirelessly Researchers from Rice University in Houston and seven other states in the US are working on a new oncotherapy sense-and-respond implant that could dramatically improve cancer outcomes. Called Targeted Hybrid Oncotherapeutic Regulation (THOR), the technology is intended primarily for the delivery […]
The post Rice University Researchers Are Developing an Implantable Cancer Therapeutic Device That May Reduce Cancer Deaths by Half appeared first on Dark Daily. (Source: Dark Daily)
Source: Dark Daily - February 23, 2024 Category: Laboratory Medicine Authors: Jillia Schlingman Tags: Laboratory Instruments & Laboratory Equipment Laboratory Management and Operations Laboratory News Laboratory Pathology Laboratory Resources Laboratory Testing Advanced Research Projects Agency for Health AI anatomic pathology ARPA-H a Source Type: news
FDA Approves 1st T-Cell Therapy For Melanoma
Authored by Amie Dahnke via The Epoch Times (emphasis ours), Melanoma cancer patients with solid tumors can turn to a new treatment thanks to the U.S. Food and Drug Administration’s (FDA) approval of a new class of immunotherapy. The new treatment may…#fda #amiedahnke #epochtimes #melanoma #amtagvi #samantharguild #aim #melanomafoundation #petermarks #hispanic (Source: Reuters: Health)
Source: Reuters: Health - February 23, 2024 Category: Consumer Health News Source Type: news
New Drug to Treat Mesothelioma Hailed as a Major Breakthrough
ADI-PEG20 or pegargiminase is being hailed as the first drug of its kind to be incorporated successfully with chemotherapy in 20 years. Researchers say this new drug could bring hope to thousands of mesothelioma survivors and their families.
The drug blocks the cancer’s food supply, ensuring the disease can’t spread. It prevents cancer cells from absorbing the amino acid arginine from the bloodstream. Arginine helps the body build protein.
Mesothelioma cells are deficient in a protein called ASS1, which allows cells to create their own arginine. If the cancer cells can’t get arginine from blood, the...
Source: Asbestos and Mesothelioma News - February 21, 2024 Category: Environmental Health Authors: Travis Rodgers Tags: Clinical Trials/Research/Emerging Treatments Mesothelioma Source Type: news
FDA Fast Tracks UV1 Vaccine Combo for Mesothelioma
The U.S. Food and Drug Administration granted fast-track designation to a new therapeutic cancer vaccine. The approval is for UV1 in combination with the immunotherapy drugs Opdivo (nivolumab) and Yervoy (ipilimumab) to manage malignant pleural mesothelioma that can’t be managed with surgery.
Therapeutic cancer vaccines, unlike preventive vaccines, treat existing cancers. Fast Track expedites the development of drug reviews for severe conditions. This way, the FDA can bring essential new drugs to patients earlier. With this designation, UV1 drug-maker Ultimovacs ASA will interact more frequently with the FDA dur...
Source: Asbestos and Mesothelioma News - February 21, 2024 Category: Environmental Health Authors: Travis Rodgers Tags: Clinical Trials/Research/Emerging Treatments Mesothelioma Source Type: news
Oncotelic Therapeutics Shares Groundbreaking Discovery In Pediatric Brainstem Tumors Demonstrating Potential For New Cancer Immunotherapy Treatments
Oncotelic Therapeutics OTLC, a therapeutics company with a focus on cancer and viral infection treatments, recently published a foundational discovery in pediatric brainstem tumors. The study showed that levels of two specific molecules – Transforming Growth Factor Beta 2 (TGF-B2) and Interferon…#interferon #ifngr2 #diffusemidlineglioma #vuongtrieu #oncotelic #sapubiosciences #sandiego #dipg #fda (Source: Reuters: Health)
Source: Reuters: Health - February 20, 2024 Category: Consumer Health News Source Type: news
FDA approves Iovance ’s Amtagvi as first T-cell therapy for a solid tumor
The T-cell therapy treatment class, which has transformed the treatment of certain blood cancers, has now reached the solid tumor field thanks to an FDA approval for a first-of-its-kind immunotherapy developed by Iovance Biotherapeutics. Called Amtagvi, or lifileucel, the drug is the first…#fda #pd1 #braf #iovance #frederickvogt #phd #vogt #jimziegler #amtagviwithmerckcos #mariafardis (Source: Reuters: Health)
Source: Reuters: Health - February 18, 2024 Category: Consumer Health News Source Type: news
In'major milestone,' FDA approves first cell therapy for solid tumors
Nearly four decades after its first conception, the first TIL therapy, an immunotherapy that harvests cancer-fighting immune cells from the patient’s own body, received accelerated approval from the Food and Drug Administration for advanced melanoma. The therapy, called Amtagvi or lifileucel from…#iovance #allisonbetofwarner #stanforduniversity #betofwarner (Source: Reuters: Health)
Source: Reuters: Health - February 17, 2024 Category: Consumer Health News Source Type: news
FDA approves Xolair as first and only medicine for children and adults with one or more food allergies
Approval is based on data from the NIH-sponsored Phase III OUtMATCH study, which showed a significantly higher proportion of food allergy patients as young as 1 year treated with Xolair could tolerate small amounts of peanut, milk, egg and cashew without an allergic reaction, compared to placeboMore than 40% of children and more than half of adults with food allergies have experienced a severe reaction at least once1,2 Detailed OUtMATCH results will be featured in a late-breaking symposiumat the 2024 AAAAI Annual MeetingBasel, 16 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food ...
Source: Roche Investor Update - February 16, 2024 Category: Pharmaceuticals Source Type: news
FDA approves Xolair as first and only medicine for children and adults with one or more food allergies
Approval is based on data from the NIH-sponsored Phase III OUtMATCH study, which showed a significantly higher proportion of food allergy patients as young as 1 year treated with Xolair could tolerate small amounts of peanut, milk, egg and cashew without an allergic reaction, compared to placeboMore than 40% of children and more than half of adults with food allergies have experienced a severe reaction at least once1,2 Detailed OUtMATCH results will be featured in a late-breaking symposiumat the 2024 AAAAI Annual MeetingBasel, 16 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food ...
Source: Roche Media News - February 16, 2024 Category: Pharmaceuticals Source Type: news
Immunotherapy Before Sarcoma Surgery Improves Outcomes
Immunotherapy can improve outcomes in patients undergoing surgery for soft-tissue sarcomaImmunotherapy and radiation therapy prior to surgery led to 90% of patients having nearly all cancer cleared from their bodiesOverall five-year survival rates... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 15, 2024 Category: General Medicine Source Type: news
